CRNX Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 7.56
- P/S (TTM)
- 213.80
- EV/EBITDA
- -13.40
Profitability & growth
- ROE (TTM)
- -42.4%
- Operating margin
- -527.0%
- Revenue growth YoY
- 2336.0%
- Dividend yield
- —
- Beta
- 0.09
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Crinetics Pharmaceuticals Inc
Company profileCrinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 6055 LUSK BOULEVARD, SAN DIEGO, CA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
